Mayo Clinic Laboratories > BioPharma Diagnostics > Testing > Oncology

ONCOLOGY

EXPERT-BACKED ASSAYS TO PROPEL THERAPEUTIC DEVELOPMENT

Offering more than 150 oncology-specific tests in nine subspecialty areas, Mayo Clinic Laboratories’ cancer tests are developed by an experienced team of board-certified geneticists, genetic counselors, and physicians. Each assay is validated in collaboration with Mayo Clinic oncologists, pathologists, and laboratorians, whose clinical expertise enables test options that improve patient care and increase efficiency.

Mayo Clinic Laboratories innovates at the speed of medical advancement and offers full-spectrum testing across the oncological arena. From broad, next-generation sequencing (NGS) panels like MayoComplete, which examines more than 500 genes for variations associated with solid tumors; to advanced fluorescence in situ hybridization (FISH) testing for monitoring chronic lymphocytic leukemia; to polymerase chain reaction (PCR) for single gene evaluation; our molecular and cytogenetic assays span the oncological spectrum, providing insights on common and rare disease to advance clinical trials and therapeutic development.

To learn more about our testing, view our biopharma-specific test catalog and full test catalog.

Test menu

Full suite of oncology testing Full suite of oncology testing
Full suite of oncology testing

Mayo Clinic Laboratories takes the lead in designing and optimizing oncology testing based on specific cancer types. Our comprehensive test menu includes evaluations that aid in providing both diagnostic and prognostic information and treatment selection guidance across the full spectrum of malignancies. By offering testing for both acquired and inherited cancers in one place, we serve as the singular source for all cancer testing.

Hereditary oncology Hereditary oncology
Hereditary oncology

Our germline test menu includes comprehensive and targeted panels as well as single gene testing. Developed in collaboration with geneticists and genetic counselors, our evaluations examine genes known for their association with cancer risk.

MayoComplete MayoComplete
MayoComplete

Including comprehensive and disease-specific panels, MayoComplete next-generation sequencing ensures each patient receives the right test and personalized answers to guide their cancer journey. Our comprehensive panel is among the largest currently available and only includes carefully vetted, actionable genes.

Comprehensive disease testing

In addition to accessing our clinically available tests, BioPharma Diagnostics partners can access oncological testing for clinical trials and be among the first to use up-and-coming tests currently in development.

  • Disease-specific NGS panels for somatic tumors, including panels specific to neuro-oncology, sarcoma, lung, colorectal, gastrointestinal stromal cancers, and more
  • MayoComplete Solid Tumor Panel, which uses NGS to evaluate 514 genes
  • Hereditary oncology NGS panels for germline assessment
  • 50+ single gene assays using FISH and PCR
  • Single gene cell-free DNA testing
  • Immunohistochemistry
  • Chromosomal microarray
  • Methylation analysis for MGMT
News and updates

The latest

Thermo Fisher Scientific: Illuminating rare cancer prognosis and improving patients’ lives

Aiming to advance understanding of hard-to-predict gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Thermo Fisher Scientific joined forces with Mayo Clinic and BioPharma Diagnostics to validate and gain U.S. regulatory clearance of a novel, automated assay aimed at detecting a biomarker associated with the progressive disease.

Learn more
Pathology Overview: Sarcoma

Pathology Overview – Melanoma

Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request Form

Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Test List

Mayo Clinic Laboratory and Pathology Research Roundup: Aug. 21

This week’s Research Roundup highlights how intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.

The Prostate Health Index <i>(phi)</i> in Prostate Cancer Risk Assessment

In this month’s “Hot Topic,” Alicia Algeciras-Schimnich, Ph.D., will provide you with valuable information regarding the utility of the prostate specific antigen test, and how the calculation of a prostate health index, or phi, can help to stratify a patient’s risk for prostate cancer and reduce unnecessary biopsies.

Pathology Overview – Neuro-Oncology

Pathology Overview – Thoracic Malignancies

Mayo Clinic Offers New Prostate Cancer Test from Beckman Coulter, Reduces Unnecessary Biopsies

The prostate health index or phi test reduces the need for prostate cancer biopsies by 30 percent.

Mayo Clinic Laboratory and Pathology Research Roundup: July 17

This week’s Research Roundup highlights postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease.

Mayo Clinic Laboratory and Pathology Research Roundup: June 5

This week’s Research Roundup highlights oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy.

Mayo Clinic Laboratory and Pathology Research Roundup: May 29

This week’s Research Roundup highlights the evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers.

View More
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

Are you a patient? Click here.